Contract sales firm PDI announced new business wins exceeding $18 million, but would not divulge the new clients' names, based on contractual agreements, according to a spokesperson. The contracts include primary care, specialty and hospital settings sales teams, according to a statement. Reps will be deployed in June, and will call on hospital-based physicians specializing in women's health, primary care and pediatrics.
Eloquest Healthcare, a dermatology specialty company, partnered with Onset Therapeutics to market Optase, a topical prescription product for the treatment of decubitus ulcers, varicose ulcers and dehiscent wounds. Optase is one of two products joint-marketed by Onset Therapeutics and Eloquest Healthcare – the second is Exactacain, a topical anesthetic spray.